Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Neurocognitive dysfunction in adult cerebellar medulloblastoma.

Harrison RA, Kesler SR, Johnson JM, Penas-Prado M, Sullaway CM, Wefel JS.

Psychooncology. 2018 Oct 13. doi: 10.1002/pon.4920. [Epub ahead of print]

PMID:
30315720
2.

Cognitive Changes in Cancer Survivors.

Hardy SJ, Krull KR, Wefel JS, Janelsins M.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):795-806. doi: 10.1200/EDBK_201179.

3.

Neurocognitive functioning is associated with functional independence in newly diagnosed patients with temporal lobe glioma.

Noll KR, Bradshaw ME, Weinberg JS, Wefel JS.

Neurooncol Pract. 2018 Aug;5(3):184-193. doi: 10.1093/nop/npx028. Epub 2017 Nov 19.

PMID:
30094046
4.

Neurocognitive Function in Adult Cancer Patients.

Harrison RA, Wefel JS.

Neurol Clin. 2018 Aug;36(3):653-674. doi: 10.1016/j.ncl.2018.04.014. Review.

PMID:
30072075
5.

Extended Measurement of the Cosmic-Ray Electron and Positron Spectrum from 11 GeV to 4.8 TeV with the Calorimetric Electron Telescope on the International Space Station.

Adriani O, Akaike Y, Asano K, Asaoka Y, Bagliesi MG, Berti E, Bigongiari G, Binns WR, Bonechi S, Bongi M, Brogi P, Buckley JH, Cannady N, Castellini G, Checchia C, Cherry ML, Collazuol G, Di Felice V, Ebisawa K, Fuke H, Guzik TG, Hams T, Hareyama M, Hasebe N, Hibino K, Ichimura M, Ioka K, Ishizaki W, Israel MH, Kasahara K, Kataoka J, Kataoka R, Katayose Y, Kato C, Kawanaka N, Kawakubo Y, Kohri K, Krawczynski HS, Krizmanic JF, Lomtadze T, Maestro P, Marrocchesi PS, Messineo AM, Mitchell JW, Miyake S, Moiseev AA, Mori K, Mori M, Mori N, Motz HM, Munakata K, Murakami H, Nakahira S, Nishimura J, de Nolfo GA, Okuno S, Ormes JF, Ozawa S, Pacini L, Palma F, Papini P, Penacchioni AV, Rauch BF, Ricciarini SB, Sakai K, Sakamoto T, Sasaki M, Shimizu Y, Shiomi A, Sparvoli R, Spillantini P, Stolzi F, Suh JE, Sulaj A, Takahashi I, Takayanagi M, Takita M, Tamura T, Tateyama N, Terasawa T, Tomida H, Torii S, Tsunesada Y, Uchihori Y, Ueno S, Vannuccini E, Wefel JP, Yamaoka K, Yanagita S, Yoshida A, Yoshida K; CALET Collaboration.

Phys Rev Lett. 2018 Jun 29;120(26):261102. doi: 10.1103/PhysRevLett.120.261102.

PMID:
30004739
6.

Neuropsychological Practice in the Oncology Setting.

Noll KR, Bradshaw ME, Rexer J, Wefel JS.

Arch Clin Neuropsychol. 2018 May 1;33(3):344-353. doi: 10.1093/arclin/acx131.

PMID:
29718081
7.

Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes.

Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ Jr, Movsas B.

Neurosurgery. 2018 Mar 30. doi: 10.1093/neuros/nyy003. [Epub ahead of print]

PMID:
29618054
8.

Neurocognitive aspects of brain metastasis.

Wefel JS, Parsons MW, Gondi V, Brown PD.

Handb Clin Neurol. 2018;149:155-165. doi: 10.1016/B978-0-12-811161-1.00012-8. Review.

PMID:
29307352
9.

Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY; Response Assessment in Neuro-Oncology (RANO) group.

Lancet Oncol. 2018 Jan;19(1):e33-e42. doi: 10.1016/S1470-2045(17)30692-7. Review.

PMID:
29304360
10.

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffietti R, van den Bent MJ, Wefel JS, Wen PY.

Lancet Oncol. 2018 Jan;19(1):e20-e32. doi: 10.1016/S1470-2045(17)30693-9. Review.

PMID:
29304358
11.

Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?

Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V.

J Clin Oncol. 2018 Feb 10;36(5):483-491. doi: 10.1200/JCO.2017.75.9589. Epub 2017 Dec 22.

12.

Energy Spectrum of Cosmic-Ray Electron and Positron from 10 GeV to 3 TeV Observed with the Calorimetric Electron Telescope on the International Space Station.

Adriani O, Akaike Y, Asano K, Asaoka Y, Bagliesi MG, Bigongiari G, Binns WR, Bonechi S, Bongi M, Brogi P, Buckley JH, Cannady N, Castellini G, Checchia C, Cherry ML, Collazuol G, Di Felice V, Ebisawa K, Fuke H, Guzik TG, Hams T, Hareyama M, Hasebe N, Hibino K, Ichimura M, Ioka K, Ishizaki W, Israel MH, Javaid A, Kasahara K, Kataoka J, Kataoka R, Katayose Y, Kato C, Kawanaka N, Kawakubo Y, Krawczynski HS, Krizmanic JF, Kuramata S, Lomtadze T, Maestro P, Marrocchesi PS, Messineo AM, Mitchell JW, Miyake S, Mizutani K, Moiseev AA, Mori K, Mori M, Mori N, Motz HM, Munakata K, Murakami H, Nakahira S, Nishimura J, de Nolfo GA, Okuno S, Ormes JF, Ozawa S, Pacini L, Palma F, Papini P, Penacchioni AV, Rauch BF, Ricciarini SB, Sakai K, Sakamoto T, Sasaki M, Shimizu Y, Shiomi A, Sparvoli R, Spillantini P, Stolzi F, Takahashi I, Takayanagi M, Takita M, Tamura T, Tateyama N, Terasawa T, Tomida H, Torii S, Tsunesada Y, Uchihori Y, Ueno S, Vannuccini E, Wefel JP, Yamaoka K, Yanagita S, Yoshida A, Yoshida K, Yuda T; CALET Collaboration.

Phys Rev Lett. 2017 Nov 3;119(18):181101. doi: 10.1103/PhysRevLett.119.181101. Epub 2017 Nov 1.

PMID:
29219544
13.

Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy.

Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS.

Mol Cell Neurosci. 2018 Jan;86:65-71. doi: 10.1016/j.mcn.2017.11.014. Epub 2017 Nov 24.

PMID:
29180229
14.

Silent Sentence Completion Shows Superiority Localizing Wernicke's Area and Activation Patterns of Distinct Language Paradigms Correlate with Genomics: Prospective Study.

Salek KE, Hassan IS, Kotrotsou A, Abrol S, Faro SH, Mohamed FB, Zinn PO, Wei W, Li N, Kumar AJ, Weinberg JS, Wefel JS, Kesler SR, Liu HA, Hou P, Stafford RJ, Prabhu S, Sawaya R, Colen RR.

Sci Rep. 2017 Sep 21;7(1):12054. doi: 10.1038/s41598-017-11192-2.

15.

Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module.

Hansen CC, Smith JB, Mohamed ASR, Mulcahy CF, Wefel JS, Hutcheson KA, Chrane K, Phan J, Frank SJ, Garden AS, Smith BD, Eichelberger H, Anderson C, McCoy C, Horiates M, Patrick C, Floris S, French C, Beadle BM, Morrison WH, Su SY, Lewis CM, Kupferman ME, Johnson JM, Skinner HD, Lai SY, Hanna EY, Rosenthal DI, Fuller CD, Gunn GB; MD Anderson Head and Neck Cancer Symptom Working Group.

Head Neck. 2017 Oct;39(10):2048-2056. doi: 10.1002/hed.24876. Epub 2017 Aug 1.

16.

Post-traumatic Stress as the Primary Cause for Cognitive Decline-Not the Whole Story, and Perhaps No Story at All.

Schagen SB, Wefel JS.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx091. No abstract available.

PMID:
28521366
17.

Reply to Freyschlag et al.

Wefel JS, Noll KR, Rao G, Cahill DP.

Neuro Oncol. 2017 Apr 1;19(4):598-599. doi: 10.1093/neuonc/now296. No abstract available.

18.

Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.

Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY.

J Neurooncol. 2017 Mar;132(1):181-188. doi: 10.1007/s11060-016-2357-9. Epub 2017 Jan 23.

19.

TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin.

Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS.

Aging (Albany NY). 2016 Dec 16;8(12):3507-3519. doi: 10.18632/aging.101144.

20.

The effect of IDH1 mutation on the structural connectome in malignant astrocytoma.

Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS.

J Neurooncol. 2017 Feb;131(3):565-574. doi: 10.1007/s11060-016-2328-1. Epub 2016 Nov 15.

21.

Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.

Wefel JS, Noll KR, Rao G, Cahill DP.

Neuro Oncol. 2016 Dec;18(12):1656-1663. Epub 2016 Aug 30.

22.

Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons.

Manchon JF, Dabaghian Y, Uzor NE, Kesler SR, Wefel JS, Tsvetkov AS.

Sci Rep. 2016 May 11;6:25705. doi: 10.1038/srep25705.

23.

Interventions for the management of fatigue in adults with a primary brain tumour.

Day J, Yust-Katz S, Cachia D, Wefel J, Katz LH, Tremont I, Bulbeck H, Armstrong T, Rooney AG.

Cochrane Database Syst Rev. 2016 Apr 13;4:CD011376. doi: 10.1002/14651858.CD011376.pub2. Review.

PMID:
27074263
24.

Neurocognitive functioning in patients with glioma of the left and right temporal lobes.

Noll KR, Ziu M, Weinberg JS, Wefel JS.

J Neurooncol. 2016 Jun;128(2):323-31. doi: 10.1007/s11060-016-2114-0. Epub 2016 Mar 29.

25.

Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS.

Neuro Oncol. 2016 Mar;18 Suppl 2:ii13-ii20. doi: 10.1093/neuonc/nov291. Review.

26.

Neurocognitive functioning and genetic variation in patients with primary brain tumours.

Wefel JS, Noll KR, Scheurer ME.

Lancet Oncol. 2016 Mar;17(3):e97-e108. doi: 10.1016/S1470-2045(15)00380-0. Epub 2016 Mar 2. Review.

27.

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU.

J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.

28.

Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma.

Noll KR, Bradshaw ME, Weinberg JS, Wefel JS.

Psychooncology. 2017 May;26(5):617-624. doi: 10.1002/pon.4046. Epub 2015 Dec 17.

29.

Verbal Learning Processes in Patients with Glioma of the Left and Right Temporal Lobes.

Noll KR, Weinberg JS, Ziu M, Wefel JS.

Arch Clin Neuropsychol. 2016 Feb;31(1):37-46. doi: 10.1093/arclin/acv064. Epub 2015 Nov 3.

30.

Response to "From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function".

Noll KR, Wefel JS.

Neuro Oncol. 2015 Oct;17(10):1421-2. doi: 10.1093/neuonc/nov176. No abstract available.

31.

Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012.

Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancré V, Lange M, Castel H.

J Pain Symptom Manage. 2015 Dec;50(6):830-41. doi: 10.1016/j.jpainsymman.2015.06.019. Epub 2015 Sep 5. Review.

PMID:
26344551
32.

Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma.

Noll KR, Weinberg JS, Ziu M, Benveniste RJ, Suki D, Wefel JS.

Neurosurgery. 2015 Nov;77(5):777-85. doi: 10.1227/NEU.0000000000000987.

33.

Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions.

Schagen SB, Klein M, Reijneveld JC, Brain E, Deprez S, Joly F, Scherwath A, Schrauwen W, Wefel JS.

EJC Suppl. 2014 Jun;12(1):29-40. doi: 10.1016/j.ejcsup.2014.03.003. Epub 2014 May 29.

34.

Neuro-Oncology Practice: Time Flies When You Are Having Fun!

Wefel JS.

Neurooncol Pract. 2014 Dec;1(4):143-144. No abstract available.

35.

Genetic Modulation of Neurocognitive Function in Glioma Patients.

Liu Y, Zhou R, Sulman EP, Scheurer ME, Boehling N, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Conrad CA, Gilbert MR, Armstrong TS, Bondy ML, Wefel JS.

Clin Cancer Res. 2015 Jul 15;21(14):3340-6. doi: 10.1158/1078-0432.CCR-15-0168. Epub 2015 Apr 22.

36.

Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Wefel JS, Kesler SR, Noll KR, Schagen SB.

CA Cancer J Clin. 2015 Mar;65(2):123-38. doi: 10.3322/caac.21258. Epub 2014 Dec 5. Review.

37.

In vitro assessment of 3 dentifrices containing fluoride in preventing demineralization of overdenture abutments and root surfaces.

Goettsche ZS, Ettinger RL, Wefel JS, Hogan MM, Harless JD, Qian F.

J Prosthet Dent. 2014 Nov;112(5):1257-64. doi: 10.1016/j.prosdent.2014.01.031. Epub 2014 Sep 30.

PMID:
25277038
38.

Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection.

Noll KR, Sullaway C, Ziu M, Weinberg JS, Wefel JS.

Neuro Oncol. 2015 Apr;17(4):580-7. doi: 10.1093/neuonc/nou233. Epub 2014 Sep 16.

39.

Reply to M.C. Chamberlain.

Gilbert MR, Dignam J, Pugh S, Armstrong TS, Wefel JS, Aldape K, Stupp R, Hegi M, Won M, Curran WJ, Mehta MP.

J Clin Oncol. 2014 May 20;32(15):1634-5. doi: 10.1200/JCO.2013.54.9717. Epub 2014 Apr 21. No abstract available.

40.

Systemically treated breast cancer patients and controls: an evaluation of the presence of noncredible performance.

Wefel JS, Kornet RL, Schagen SB.

J Int Neuropsychol Soc. 2014 Apr;20(4):357-69. doi: 10.1017/S1355617714000022. Epub 2014 Mar 10.

PMID:
24607070
41.

A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP.

N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573.

42.

Erosive potentials of brewed teas.

Hendricks JL, Marshall TA, Harless JD, Hogan MM, Qian F, Wefel JS.

Am J Dent. 2013 Oct;26(5):278-82.

PMID:
24479280
43.

A prospective study of cognitive function in men with non-seminomatous germ cell tumors.

Wefel JS, Vidrine DJ, Marani SK, Swartz RJ, Veramonti TL, Meyers CA, Hoekstra HJ, Hoekstra-Weebers JE, Gritz ER.

Psychooncology. 2014 Jun;23(6):626-33. doi: 10.1002/pon.3453. Epub 2013 Dec 16.

44.

TETRA observation of gamma-rays at ground level associated with nearby thunderstorms.

Ringuette R, Case GL, Cherry ML, Granger D, Guzik TG, Stewart M, Wefel JP.

J Geophys Res Space Phys. 2013 Dec;118(12):7841-7849. Epub 2013 Dec 6.

45.

Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.

Jones D, Vichaya EG, Wang XS, Sailors MH, Cleeland CS, Wefel JS.

Cancer. 2013 Dec 1;119(23):4188-95. doi: 10.1002/cncr.28323. Epub 2013 Sep 16.

46.

Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.

Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M.

J Clin Oncol. 2013 Nov 10;31(32):4076-84. doi: 10.1200/JCO.2013.49.6067. Epub 2013 Oct 7.

47.

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP.

J Clin Oncol. 2013 Nov 10;31(32):4085-91. doi: 10.1200/JCO.2013.49.6968. Epub 2013 Oct 7.

48.

Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.

Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY; Response Assessment in Neuro-Oncology (RANO) group.

Lancet Oncol. 2013 Sep;14(10):e407-16. doi: 10.1016/S1470-2045(13)70308-5. Review.

PMID:
23993385
49.

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY; Response Assessment in Neuro-Oncology (RANO) group.

Lancet Oncol. 2013 Sep;14(10):e396-406. doi: 10.1016/S1470-2045(13)70311-5. Review.

PMID:
23993384
50.

Chemotherapy-related changes in cognitive functioning.

Schagen SB, Wefel JS.

EJC Suppl. 2013 Sep;11(2):225-32. doi: 10.1016/j.ejcsup.2013.07.007. Review. No abstract available.

Supplemental Content

Support Center